Literature DB >> 2549430

Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart.

D Brunkhorst1, H v der Leyen, W Meyer, R Nigbur, C Schmidt-Schumacher, H Scholz.   

Abstract

(1) This study was performed to elucidate the relation between positive inotropy and phosphodiesterase inhibition in the heart. Therefore, the influence on the activity of guinea-pig cardiac phosphodiesterase (PDE) I-III separated by DEAE-cellulose anion exchange chromatography was investigated for the new cardiotonic agents pimobendan, its metabolite UD-CG 212 Cl and milrinone. These effects were compared with those of various other PDE inhibitors such as IBMX, zaprinast, rolipram and AR-L 57 Cl. A selectivity factor (SF, mean of the IC50 values for PDE I and II inhibition divided by the IC50 for PDE III) was calculated for each drug. The greater this value the more selective was the PDE III inhibition. (2) UD-CG 212 Cl was the most potent (IC50 = 0.19 mumol/l) and most selective inhibitor of PDE III with a SF of 869. Also selective PDE III inhibitors were pimobendan (SF = 50.5) and milrinone (SF = 70.0) with slightly smaller potencies (IC50 = 2.40 and 1.52 mumol/l, respectively). Zaprinast and rolipram preferentially inhibited PDE I and II, respectively. IBMX and AR-L 57 Cl inhibited PDE I-III unselectively with similar potencies for all isoenzymes. (3) The PDE inhibitory effects of all substances were compared with their influence on force of contraction (electrically driven papillary muscles) and on frequency of beating (spontaneously beating right auricles) in guinea-pig hearts, thus in preparations of the same species. UD-CG 212 Cl and pimobendan resembled each other in their maximal positive inotropic effects with potencies (EC50) of 1.8 mumol/l and 6.0 mumol/l, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549430     DOI: 10.1007/BF00167264

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  28 in total

1.  Effects of several phosphodiesterase-inhibitors on guinea-pig myocardium.

Authors:  M Korth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-03       Impact factor: 3.000

Review 2.  A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.

Authors:  R E Weishaar; M H Cain; J A Bristol
Journal:  J Med Chem       Date:  1985-05       Impact factor: 7.446

3.  Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.

Authors:  R E Weishaar; S D Burrows; D C Kobylarz; M M Quade; D B Evans
Journal:  Biochem Pharmacol       Date:  1986-03-01       Impact factor: 5.858

4.  Usefulness of pimobendan in the treatment of heart failure.

Authors:  D J Duncker; F J van Dalen; J M Hartog; J M Lamers; R J Rensen; P R Saxena; P D Verdouw
Journal:  Arzneimittelforschung       Date:  1986-12

5.  Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone.

Authors:  K Fujino; N Sperelakis; R J Solaro
Journal:  Circ Res       Date:  1988-11       Impact factor: 17.367

6.  UD-CG 115--a cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea-pig papillary muscle.

Authors:  P Honerjäger; A Heiss; M Schäfer-Korting; G Schönsteiner; M Reiter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-03       Impact factor: 3.000

7.  Molecular basis for the cardiovascular activities of amrinone and AR-L57.

Authors:  J S Hayes; N Bowling; G B Boder; R Kauffman
Journal:  J Pharmacol Exp Ther       Date:  1984-07       Impact factor: 4.030

8.  Comparative cardiovascular effects of three benzimidazole derivatives, AR-L 57 BS, AR-L 100 BS, and AR-L 115 BS.

Authors:  W Diederen; R Kadatz
Journal:  Arzneimittelforschung       Date:  1981

9.  Phosphodiesterase-inhibiting properties of newer inotropic agents.

Authors:  H Scholz; W Meyer
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

10.  Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts.

Authors:  T Bethke; D Brunkhorst; H von der Leyen; W Meyer; R Nigbur; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

View more
  18 in total

1.  Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.

Authors:  M A Movsesian; C J Smith; J Krall; M R Bristow; V C Manganiello
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

2.  Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle.

Authors:  M Galvan; C Schudt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

3.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

4.  E-1020, a water soluble imidazopyridine, has direct effects on Ca(2+)-dependent force and ATP hydrolysis of canine and bovine cardiac myofilaments.

Authors:  F M Powers; K A Palmiter; R J Solaro
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

5.  Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium.

Authors:  M Ungerer; M Böhm; R H Schwinger; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

6.  Use of pimobendan in feline congenital heart failure.

Authors:  Shannon Wainberg
Journal:  Can Vet J       Date:  2013-12       Impact factor: 1.008

Review 7.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

8.  Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.

Authors:  T Bethke; W Meyer; W Schmitz; H Scholz; B Stein; K Thomas; H Wenzlaff
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

9.  Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties.

Authors:  J Schneider; E Beck; C Heers; C Conrad; D de Chaffoy de Courcelles; B Wilffert; T Peters
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

Review 10.  Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.

Authors:  T A Fischer; R Erbel; N Treese
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.